This study was published in the Journal of the American Medical Association 2007 Mar 28;297(12):1344-53
Study title and authors:
Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial.
Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O'Leary DH, Grobbee DE, Bots ML; METEOR Study Group.
Department of Medicine, Wake Forest University, Winston-Salem, NC 27157, USA. jrcrouse@wfubmc.edu
This study can be accessed at: http://www.ncbi.nlm.nih.gov/pubmed/17384434
This study investigated the effects of statins in participants with a low risk of heart disease. The two year study was a randomised, double-blind, placebo-controlled trial of 984 individuals, average age 57 years. The participants received either a daily 40-mg dose of rosuvastatin or placebo.
The study found:
(a) Cholesterol levels reduced by 33% in the statin users and remained the same in those on placebo.
(b) Low density lipoprotein (LDL) cholesterol levels reduced by 49% in the statin users and remained the same in those on placebo.
(c) Statin users had a 21% increased risk of death compared to placebo.
(d) Statin users had a 423% increased risk of a serious adverse cardiovascular event compared to placebo.
(e) Statin users had a 4% increased risk of any adverse event compared to placebo.
(f) Statin users had a 5% increased risk of developing cancer compared to placebo.
(g) Statin users had a 5% increased risk of muscle pain compared to placebo.
(h) Statin users had a 121% increased risk of elevated liver enzymes compared to placebo.
(i) Statin users had a 56% increased risk of developing arthritis compared to placebo.
